This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arnold, J. D.
Right arrow Articles by Miller, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arnold, J. D.
Right arrow Articles by Miller, R. M.

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1973 February; 3(2): 207-213
Copyright © 1973 American Society for Microbiology. All Rights Reserved.

A Phenanthrene Methanol (WR 33063) for Treatment of Acute Malaria

J. D. Arnold, D. C. Martin, P. E. Carson, K. H. Rieckmann, D. Willerson Jr., D. F. Clyde and R. M. Miller

Harry S. Truman Research Laboratory, Kansas City, Missouri 64108
Laboratory for Tropical Diseases, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612
University of Maryland School of Medicine, Baltimore, Maryland 21201

ABSTRACT

WR 33063, a phenanthrene methanol, was studied in human volunteers for tolerance and toxicity. In normal volunteers, it was possible to give 4.6 g in four divided doses without adverse effect for 10 days. At this dose level, there was neither evidence of photosensitivity nor adverse renal or cardiac effect. At a dose level of 1.6 g in four divided doses for 6 days, WR 33063 cured 18 of 23 nonimmune volunteers infected with the Smith strain of Plasmodium falciparum from Vietnam. In addition, infections due to the Marks and Braithwaite Vietnam strains were also treated because these strains represent a major therapeutic challenge to chloroquine; six of six and two of three volunteers, respectively, were cured. With the Malayan Camp strain, 1.6 g in four divided doses for 6 days cured all of five volunteers. The African Uganda I strain of chloroquine-responsive malaria was even more responsive to WR 33063; all of six men who received 1.6 g in four divided doses for 6 days were cured, and all of three men who received this same dosage for 3 days were cured. One subject infected with a Haitian strain of P. falciparum was treated and cured. Blood-induced infections with the Chesson strain of P. vivax also responded well to WR 33063 with four of five men cured. In all, 52 men received WR 33063 in tolerance trials, and 59 men with experimental malaria and one man with clinical malaria were treated with WR 33063.

Antimicrob Agents Chemother. 1973 February; 3(2): 207-213
Copyright © 1973 American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Trenholme, C., Williams, R., Desjardins, R., Frischer, H, Carson, P., Rieckmann, K., Canfield, C. (1975). Mefloquine (WR 142,490) in the treatment of human malaria. Science 190: 792-794 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»